Efficacy and safety of rozanolixizumab in severe fibromyalgia: a phase 2A randomised, double-blind, placebo-controlled, multicentre trial

The Lancet Rheumatology · Elsevier

Аннотация

Publication date: November 2026 Source: The Lancet Rheumatology, Volume 8, Issue 11 Author(s): Andreas Goebel, Paul Meisner, Gustaf Rydevik, Alexander Vugler, Yiannis Ioannou, Ekaterina Tankisheva, Colin Ewen, Jérémy Lambert, Stevan Shaw, Ivan Matthews

Читать у издателя →

Похожие статьи